Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues?

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. ResMed Inc. (NYSE:RMD) is among the best healthcare stocks.

TheFly reported on June 22 that KeyBanc adjusted its price target for RMD to $266 from $290 while maintaining an Overweight rating on the shares. The firm noted that insights from the SLEEP APSS Meeting in Baltimore, along with further analysis of the obstructive sleep apnea (OSA) competitive environment, strengthened its confidence in ongoing patient demand trends. KeyBanc highlighted continued momentum in the OSA and CPAP markets, supported by increasing demand growth from factors such as GLP-1 adoption and consumer wearable technologies.

Earlier, on June 1, ResMed Inc. (NYSE:RMD) completed its acquisition of Noctrix Health, Inc., a medical device company focused on wearable therapies for chronic neurological conditions. The transaction expands ResMed's sleep health portfolio into the treatment of Restless Legs Syndrome (RLS), addressing an area with significant unmet medical needs. Noctrix's Nidra TOMAC Therapy, an FDA De Novo classified, non-invasive treatment, is designed to help reduce symptoms of moderate-to-severe RLS and improve sleep quality for adults with limited treatment options. Through the acquisition, RMD aims to integrate Noctrix's technology into its connected health ecosystem, strengthening its focus on improving patient outcomes and expanding access to innovative home-based care solutions.

ResMed Inc. (NYSE:RMD) is a global digital health and medical device company specializing in sleep apnea, respiratory care, and connected healthcare solutions across more than 140 countries.

While we acknowledge the potential of RMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.